Vaxart announced positive preliminary data from phase 1 clinical trial evaluating oral COVID-19 tablet vaccine candidate
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyメs rapid point-of-care test…
On Feb. 3, 2021, Quidel announced the opening of a new manufacturing facility in Carlsbad, CA that was…
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new タ150m collaboration, building on their existing relationship, to…
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
On Jan. 30, 2021, as the COVID-19 pandemic continued to surge in the U.S., the CDC implemented a…
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
On Jan. 29, 2021, OraSure Technologies announced its OMNIgeneᆴᄋORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab…
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyメs Phase 2 clinical trial of Brilacidin for treating…
On Jan. 28, 2021, National Institutes of Health (NIH) researchers reported that pregnant women who experienced severe symptoms…
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
On Jan. 28, 2021, OraSure Technologies announced its OMNIgeneᆴᄋORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary…
On Jan. 27, 2021, Ajinomoto Bio-Pharma Services and Humanigen announced the companies will be expanding their manufacturing agreement…
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
On Jan. 27, 2021, Eli Lilly, Vir Biotechnology and GlaxoSmithKline announced a collaboration to evaluate a combination of…
On Jan. 27, 2021, Moderna confirmed that the Company is in discussion with the U.S. government to purchase…
On Jan. 27, 2021, Heat Biologics announced the publication of additional preclinical COVID-19 results in Frontiers in Immunology,…
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…